☆
Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model
Christina Harlev, Elisabeth Krogsgaard Petersen, Mats Bue, Lone Kjeld Petersen, Johanne Gade Lilleøre, Anne Vibeke Schmedes, Bo Martin Bibby, Maiken Stilling
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy
Matthieu Gracia, Sabrina Marsili, Julien Vintejoux, Laurence Gladieff, Etienne Chatelut, Fabienne Thomas
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer
Takehiko Sambe, Chiyo K. Imamura, Noriko Hida, Taigi Yamazaki, Takuya Mizukami, Kakei Ryu, Koya Fukunaga, Taisei Mushiroda, Haruna Miyakawa, Shigeto Uchiyama, Naoki Uchida, Shinichi Kobayashi
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)
Lin Fang, Xin Jiang, Kexiu Song, Ping Shi, Li Wang, Lingmei Xu, Xianghui Duan, Fei Liu, Feifei Sun, Rongxin Ban, Yaping Ma, Chenjing Wang, Yu Cao
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity
Elizabeth Cui, Samantha Medwid, Ute I. Schwarz, Richard B. Kim
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer
Gabriel A. Brooks, Dylan B. Ness, Kathryn C. Hourdequin, Gregory H. Ripple, Manik Amin, Sierra Lord-Halvorson, Wahab A. Khan, Sophie J. Deharvengt, Vincent Busque, Konstantin H. Dragnev, Wenyan Zhao, Tor D. Tosteson, Lionel D. Lewis
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
Abstract Purpose Standard dosing of infusional 5-FU results in subtherapeutic drug exposure for up to half of all patients. We evaluated plasma uracil concentration and DPYD rs4294451 genotype as candidate predictors of individual-level...
☆
6-gingerol alleviates chemotherapy-induced nausea and vomiting by inhibiting ferroptosis via the regulation of iron homeostasis
Wan Liang, Lei Feng, Siyu Han, Chenglu Yang, Binbin Ye, Ziyao Mo, Ke Nie
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions
Lina Eltaib, Muhammad Afzal, Chandana Maji, H. Malathi, Kavita Goyal, Haider Ali, Gaurav Gupta, Md Sadique Hussain
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
Martina Catalano, Gestiana Cekrezi, Irene De Gennaro Aquino, Delia Ravizza, Alexandra Paulet, Kristian Shtembari, Claudia De Angelis, Roberto Petrioli, Daniele Generali, Giandomenico Roviello
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
Abstract Background CDK4/6 inhibitors have transformed treatment for HR + HER2 − advanced breast cancer (aBC). However, adverse events (AEs) often lead to dose adjustments or discontinuation, potentially impacting outcomes. This study...
☆
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
Claire Brillac, Dorothée Sémiond, Corina Oprea, André Baruchel, C. Michel Zwaan, Laurent Nguyen
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-12-01
☆
Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer
Stuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran, Robert A. Parise, Robert Bies, David Quinn, Kristopher Attwood, Xiaozhuo Liu, Kelly Green, Jason S. Kirk, Jan H. Beumer, Dean G. Tang, Gurkamal Chatta
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-29
Abstract Purpose Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be effectively targeted by...
☆
A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial
Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Venkata Ramalingayya Grandhi, Javeed Mohammad, Sanyasirao K. S. S. V. V., Mamatha Reddy Dundigalla, Pavan Kumar Madala
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-24
☆
Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancer
Geonwoo Lee, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-ichi Fujita
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-24
☆
Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review
Yu Yan, Xin Zheng, Xue Zhao, Xiaoyan Si, Li Zhang
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-22
☆
Assessing plastic waste associated with LC-MS/MS method validation procedures
Romain Beziat, Chan Laurent-Britel, Samuel Huguet, Manon Launay
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-21
☆
Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling
Hui Chen, Shixing Zhu, Anqi Yang, Xu Li, Xunqiang Wang, Wei Zhao, Xin Wang, Ding Yu
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-21
☆
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report
Madeline L. Norris, David L. DeRemer, Julio D. Duarte, George P. Kim, Thomas J. George
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-21
☆
Transient receptor melastatin channel in colorectal cancer: pathophysiological mechanisms and a promising drug target
Ala’a S. Shraim, Manal A. Abbas
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-21
☆
Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration data
Sakiko Kimura, Ken-ichi Sako, Nao Kikkawa, Yuta Nakamaru, Shunsuke Matsuo, Kana Kusaba, Mai Fujita, Keisuke Kidoguchi, Sho Okamoto, Yukie Yoda, Shinya Kimura, Chisato Shimanoe
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-20
☆
Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences
Yangqingqing Zhou, Wunan Huang, Xinyue Hang, Yanlin He, Ruiyuan He, Chaosheng Gan
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-19
☆
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity
Rob ter Heine, Bianca J. C. van den Bosch, Robin M. van Geel, Wouter H. van Geffen, Lizza E. L. Hendriks, Michel M. van den Heuvel, Simon E. Koele, Adrianus J. de Langen, Thijs H. Oude Munnink, Anthonie J. van der Wekken
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-11-07
Abstract Purpose The combination of lazertinib and amivantamab has shown superior efficacy over first line osimertinib in EGFR-mutated metastatic non-small cell lung cancer, but is associated with significant toxicity and high costs....
☆
Thrombosis and cancer what do the recommandations say
Sihame Lkhoyaali, Oumaima Lamsyah, Roda Hassan Eltigani, Wydad Nadir, Saber Boutayeb, Hassan Errihani
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-27
☆
Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy—A case report
Lotte M. G. Hulskotte, Loek A. W. de Jong, Alwin D. R. Huitema, Joost Sijm, Ingrid Desar, Minke Smits, Nielka P. van Erp
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-22
Abstract Background High-dose chemotherapy (HDCT) combined with autologous stem cell transplantation (ASCT) rescue is an effective treatment option for relapsed or refractory germ-cell tumors. The TI-CE regimen, consisting of paclitaxel...
☆
Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report
Reema Patel, John F. Deeken
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-22
☆
Mirdametinib: FDA approved MEK inhibitor for neurofibromatosis type 1
Saara, Shweta Kamboj, Dimpy Rani
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-18
☆
Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer
Sandip M. Prasad, Michael J. Louie, Brent Burger, Victoria Tsurutis, Nikky Ugwuoke, Dalit Strauss-Ayali
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-11
☆
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results
Jayesh Desai, Sanjeev Deva, Bo Gao, Kunyu Yang, Kenneth J. O’Byrne, Meili Sun, Tianshu Liu, Tarek Meniawy, Xinmin Yu, Mark Voskoboynik, Diwakar Davar, Marco Matos, Shiangjiin Leaw, Tahmina Rahman, Xiaofei Qu, Hugh Giovinazzo, Xin Chen, Yan Dong, Daphne Day
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-08
☆
Dosing chemotherapy in children with obesity: literature review and evaluation of local practices
Joshua Convert, Pierre Leblond, Perrine Marec-Berard, Anthony Ceraulo, Benoit Dumont, Michael Philippe
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-06
☆
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety
Małgorzata Pieniążek, Marcin Kubeczko, Manuela Las-Jankowska, Anna Polakiewicz-Gilowska, Aleksandra Łacko, Michał Jarząb, Zuzana Bielčiková, Renata Pacholczak-Madej, Miroslawa Püsküllüoğlu
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-04
Abstract Background Sacituzumab govitecan (SG) is approved for metastatic triple-negative breast cancer in ≥ 2 line setting at 10 mg/kg IV on Days 1 and 8 (21-day cycle). Trials confirmed its superiority over 8 mg/kg with manageable...
☆
Modulation of prostaglandin-endoperoxide synthase-2 (PTGS2) mediated VEGF-signalling pathway by oral metronomic chemotherapy in locally advanced oral squamous cell Carcinoma: A brief report
Mehta Vedant Kamal, Akhil Palod, Preetiparna Parida, Ananth Pai, Krishna Sharan, Vijetha Shenoy Belle, Rama Rao Damerla, Mahadev Rao, Naveena A. N. Kumar
Cancer Chemotherapy and Pharmacology
· Онкология
· 2025-10-04